Evidence map›Paper›PMID 40444626›Full record

ReviewCNS & neurological disorders drug targets2025

Advances in Diagnostic Approaches for Alzheimer's Disease: From Biomarkers to Deep Learning Technology.

Muhammad Asif, Hamid Ullah, Nelofer Jamil, Musarat Riaz, Maryam Zain, Peter Natesan Pushparaj, Mahmood Rasool

Abstract readReview
PubMed Publisher
In one paragraph

Review in CNS & neurological disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad AsifDepartment of Biotechnology and ORIC, Balochistan University of Information Technology, Engineering & Management Sciences (BUITEMS), Quetta, Pakistan.
Hamid UllahDepartment of Chemistry, Balochistan University of Information Technology, Engineering and Management Sciences, Quetta, Pakistan.
Nelofer JamilDepartment of Chemistry, Sardar Bahadur Khan Women's University Quetta, Pakistan.
Musarat RiazDepartment of Chemistry, Sardar Bahadur Khan Women's University Quetta, Pakistan.
Maryam ZainDepartment of Biochemistry and Biotechnology, The Women University, Multan, Pakistan.
Peter Natesan PushparajInstitute of Genomic Medicine Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Mahmood RasoolInstitute of Genomic Medicine Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0003-2997-5891

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a devastating neurological disorder that affects humans and is a major contributor to dementia. It is characterized by cognitive dysfunction, impairing an individual's ability to perform daily tasks. In AD, nerve cells in areas of the brain related to cognitive function are damaged. Despite extensive research, there is currently no specific therapeutic or diagnostic approach for this fatal disease. However, scientists worldwide have developed effective techniques for diagnosing and managing this challenging disorder. Among the various methods used to diagnose AD are feedback from blood relatives and observations of changes in an individual's behavioral and cognitive abilities. Biomarkers, such as amyloid beta and measures of neurodegeneration, aid in the early detection of Alzheimer's disease (AD) through cerebrospinal fluid (CSF) samples and brain imaging techniques like Magnetic Resonance Imaging (MRI). Advanced medical imaging technologies, including X-ray, CT, MRI, ultrasound, mammography, and PET, provide valuable insights into human anatomy and function. MRI, in particular, is non-invasive and useful for scanning both the structural and functional aspects of the brain. Additionally, Machine Learning (ML) and deep learning (DL) technologies, especially Convolutional Neural Networks (CNNs), have demonstrated high accuracy in diagnosing AD by detecting brain changes. However, these technologies are intended to support, rather than replace, clinical assessments by medical professionals.

Indexed as

Alzheimer DiseaseBiomarkersDeep LearningBrainHumansMagnetic Resonance ImagingNeuroimagingBiomarkersADcomputed tomographydeep learning.machine learningmagnetic resonance imaging

Identifiers

PMID40444626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.